prev next front |1 |2 |3 |4 |5 |6 |7 |8 |9 |10 |11 |12 |13 |14 |15 |16 |17 |18 |19 |review

EG: experimental group

CG: control group

  • Measurements of results: main endpoint: proportional change in the number of packages of tenoxicam, piroxicam y diclofenac prescribed; secondary endpoint: change in the cost per prescription for all NSAIDs prescribed.
  • Intervention: the experimental group received an evidence-based educational outreach visit; the placebo group received information in a routine pharmaceutical session; the control group received no information on the topic during the duration of the study.